News | Cardiovascular Business | March 22, 2022

Medtronic Appoints New Operating Unit Presidents

Que Dallara joins as EVP & President, Diabetes; Mike Marinaro named President, Surgical Robotics; Dr. Kweli Thompson named President, Cardiac Rhythm Management

Medtronic, a global leader in healthcare technology, has announced leadership transitions for three of its Operating Units – Diabetes, Surgical Robotics, and Cardiac Rhythm Management – bringing in critical skills and capabilities and creating opportunities for internal talent.

From left: Dallara, Marinaro, Thompson


March 22, 2022 – Medtronic, a global leader in healthcare technology, has announced leadership transitions for three of its Operating Units – Diabetes, Surgical Robotics, and Cardiac Rhythm Management – bringing in critical skills and capabilities and creating opportunities for internal talent.

"The future of medical technology requires strong leadership in data science, artificial intelligence, and robotics, all of which make these three Operating Unit President roles some of the most important and dynamic leadership opportunities in our industry," said Geoff Martha, Medtronic chairman and chief executive officer. "These appointments not only strengthen our businesses and build our technology expertise; they also further establish Medtronic as a destination for world-class talent."

Que Dallara joins as Executive Vice President and Operating Unit President, Diabetes
DallaraQue Dallara joins the Medtronic Executive Committee reporting to Chairman and CEO Geoff Martha on May 2, 2022. Dallara comes from Honeywell where she served as President and CEO of Honeywell Connected Enterprise, and earlier as SVP and chief commercial officer. She also held general manager and strategy roles at TE Connectivity Ltd. and Microsoft, after working at McKinsey in her early career.

Experienced in new product development and commercialization, Dallara has managed robust product portfolios, led end-to-end R&D innovation, and business development initiatives that strengthened organic and inorganic company growth. She will bring unique and meaningful perspective and experiences to the Diabetes business and Medtronic Executive Committee.

In this role, Dallara succeeds Sean Salmon, executive vice president and president, Cardiovascular Portfolio and Diabetes Operating Unit, who now turns to focus exclusively on leading the Cardiovascular Portfolio. Salmon will ensure continuity and support Dallara's transition into the Diabetes business. He continues as a member of the Medtronic Executive and Capital Allocation Committees, helping to lead the company's enterprise strategy.

Mike Marinaro named Operating Unit President, Surgical Robotics
MarinaroMike Marinaro joins the Medical Surgical Portfolio leadership team reporting to Executive Vice President and President, Bob White. Marinaro is a seasoned leader with more than 20 years of experience and success at Medtronic. Previously, he led the Cardiac Rhythm Management Operating Unit with annualized revenue of more than $4 billion. Under Marinaro's leadership, the business launched and scaled the Micra leadless pacemaker product line to more than $400 million annualized revenue.

Marinaro is known for his strong focus on innovation, commercialization, and scaling businesses and building inclusive work environments - ideal attributes to help continue Surgical Robotics' growth trajectory.

Marinaro succeeds Megan Rosengarten, who is taking a planned six-month sabbatical to spend more time with her family with the full support of Medtronic. Rosengarten has successfully led the Surgical Robotics business for the past four years, steering the Hugo RAS System from early development to commercialization, and leading the acquisition of the Digital Surgery business.

Dr. Kweli Thompson named Operating Unit President, Cardiac Rhythm Management
ThompsonDr. Thompson joins the Cardiovascular Portfolio leadership team reporting to Salmon. Dr. Thompson is an accomplished medical technology leader with two decades of experience in business development, clinical research, product marketing, and general management. Dr. Thompson is known for accelerating performance, growth, and profitability. Previously, as vice president and general manager of the Cardiac Resynchronization and Defibrillation Solutions businesses, a part of Cardiac Rhythm Management, he led Defibrillation Solutions to the highest market share in three years and the highest Cardiac Resynchronization Therapy market share in more than a decade.

 

For more information: https://www.medtronic.com/us-en/


Related Content

News | Cardiovascular Business

July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing ...

Home July 29, 2024
Home
News | Cardiovascular Business

July 18, 2024 — Circle Cardiovascular Imaging, a developer of artificial intelligence (AI)-driven cardiovascular imaging ...

Home July 18, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Guidehealth, an artificial intelligence (AI)-enabled healthcare services company, has announced a ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Edwards Lifesciences announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 11, 2024 — Medical device company R3 Vascular Inc., developer of novel, best-in-class bioresorbable scaffolds for ...

Home July 11, 2024
Home
News | Cardiovascular Business

July 9, 2024 — Disparities in cardiovascular disease outcomes between urban and rural areas continue to widen, yet ...

Home July 09, 2024
Home
Feature | Cardiovascular Business

The DAIC team wishes you a safe and happy 4th of July!

Home July 04, 2024
Home
News | Cardiovascular Business

July 3, 2024 — Over the past decade, 342 cardiology clinics have been acquired by private equity firms, with over 94% of ...

Home July 03, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

From FDA approvals to new clinical trials, here is a look at DAIC's top-read content during the month of June: 1 ...

Home July 02, 2024
Home
News | Cardiovascular Business

July 1, 2024 — CVRx, Inc., a commercial-stage medical device company, announced three additions to its senior leadership ...

Home July 01, 2024
Home
Subscribe Now